Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease
ABSTRACT Background Fatigue affects 40% to 50% of all PD patients and is a leading cause of disability, with no clearly established or efficacious established treatments. Methods In this double‐blinded, placebo‐controlled, pilot trial, we investigated whether rasagiline improved fatigue among PD pat...
Gespeichert in:
| Veröffentlicht in: | Movement disorders 2015-11, Vol.30 (13), p.1825-1830 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1830 |
|---|---|
| container_issue | 13 |
| container_start_page | 1825 |
| container_title | Movement disorders |
| container_volume | 30 |
| creator | Lim, Thien Thien Kluger, Benzi M. Rodriguez, Ramon L. Malaty, Irene A. Palacio Jr, Rafael Ojo, Oluwadamilola O. Patel, Shnehal Gujrati, Yogesh Nutter, Benjamin Swartz, Camille Hennessy, Carol Fernandez, Hubert H. |
| description | ABSTRACT
Background
Fatigue affects 40% to 50% of all PD patients and is a leading cause of disability, with no clearly established or efficacious established treatments.
Methods
In this double‐blinded, placebo‐controlled, pilot trial, we investigated whether rasagiline improved fatigue among PD patients. Subjects were randomized to 1 mg daily of rasagiline or placebo for 12 weeks. The primary endpoint was a change in the Modified Fatigue Impact Scale from baseline to week 12.
Results
Thirty PD subjects (16 men), with Modified Fatigue Impact Scale baseline score of 67 ± 15, were randomized (16 to rasagiline vs. 14 to placebo). Significant improvement was noted in the mean Modified Fatigue Impact Scale score of the rasagiline group (12 points) as compared to placebo (8.5 points) from baseline to week 12 (P = 0.003).
Conclusion
In this pilot study, rasagiline at a dose of 1 mg per day improved fatigue. Larger randomized studies are needed to confirm this finding. © 2015 International Parkinson and Movement Disorder Society. |
| doi_str_mv | 10.1002/mds.26429 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1780517394</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1760893165</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4249-78be915264cb5f88f92aa46a76f862a219d072a063848455f304365161c4d9643</originalsourceid><addsrcrecordid>eNqN0ctOGzEYBWALgUqALngBZIlFYTHB98uyCiUt4lKlVF1azoxNDXNJ7RlB3r5OE1hUQkJeWLK-_8j2AeAQozFGiJw1VRoTwYjeAiPMKS4U4XIbjJBSvKBY8V2wl9IDQhhzLD6AXSKk0IzrEbic2WTvQx1aB30XYf_bwbRsFn3X2D6UsI_O9o1re9h56PPR_eBgaOF3Gx9Dm7r2U4JVSM4mdwB2vK2T-7jZ98HPiy93k6_F1e302-TzVVEywnQh1dxpzPN9yzn3SnlNrGXCSuGVIJZgXSFJLBJUMcU49xQxKvK9cckqLRjdByfr3EXs_gwu9aYJqXR1bVvXDclgqRDHkur3UIGUpljwTI__ow_dENv8kKx4XlrhlTpdqzJ2KUXnzSKGxsalwcisujC5C_Ovi2yPNonDvHHVq3z5_AzO1uAp1G75dpK5Pv_xElmsJ0Lq3fPrRO7CCEklN79upuZcqpmYikuj6F8Ly58F</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1757579815</pqid></control><display><type>article</type><title>Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lim, Thien Thien ; Kluger, Benzi M. ; Rodriguez, Ramon L. ; Malaty, Irene A. ; Palacio Jr, Rafael ; Ojo, Oluwadamilola O. ; Patel, Shnehal ; Gujrati, Yogesh ; Nutter, Benjamin ; Swartz, Camille ; Hennessy, Carol ; Fernandez, Hubert H.</creator><creatorcontrib>Lim, Thien Thien ; Kluger, Benzi M. ; Rodriguez, Ramon L. ; Malaty, Irene A. ; Palacio Jr, Rafael ; Ojo, Oluwadamilola O. ; Patel, Shnehal ; Gujrati, Yogesh ; Nutter, Benjamin ; Swartz, Camille ; Hennessy, Carol ; Fernandez, Hubert H.</creatorcontrib><description>ABSTRACT
Background
Fatigue affects 40% to 50% of all PD patients and is a leading cause of disability, with no clearly established or efficacious established treatments.
Methods
In this double‐blinded, placebo‐controlled, pilot trial, we investigated whether rasagiline improved fatigue among PD patients. Subjects were randomized to 1 mg daily of rasagiline or placebo for 12 weeks. The primary endpoint was a change in the Modified Fatigue Impact Scale from baseline to week 12.
Results
Thirty PD subjects (16 men), with Modified Fatigue Impact Scale baseline score of 67 ± 15, were randomized (16 to rasagiline vs. 14 to placebo). Significant improvement was noted in the mean Modified Fatigue Impact Scale score of the rasagiline group (12 points) as compared to placebo (8.5 points) from baseline to week 12 (P = 0.003).
Conclusion
In this pilot study, rasagiline at a dose of 1 mg per day improved fatigue. Larger randomized studies are needed to confirm this finding. © 2015 International Parkinson and Movement Disorder Society.</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.26429</identifier><identifier>PMID: 26769459</identifier><identifier>CODEN: MOVDEA</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Double-Blind Method ; fatigue ; Fatigue - drug therapy ; Fatigue - etiology ; Female ; Follow-Up Studies ; Humans ; Indans - therapeutic use ; Male ; Middle Aged ; Movement disorders ; Neuroprotective Agents - therapeutic use ; Parkinson Disease - complications ; Parkinson's disease ; Pilot Projects ; rasagiline ; Severity of Illness Index ; Statistics, Nonparametric ; Treatment Outcome</subject><ispartof>Movement disorders, 2015-11, Vol.30 (13), p.1825-1830</ispartof><rights>2015 International Parkinson and Movement Disorder Society</rights><rights>2015 International Parkinson and Movement Disorder Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4249-78be915264cb5f88f92aa46a76f862a219d072a063848455f304365161c4d9643</citedby><cites>FETCH-LOGICAL-c4249-78be915264cb5f88f92aa46a76f862a219d072a063848455f304365161c4d9643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmds.26429$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmds.26429$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26769459$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lim, Thien Thien</creatorcontrib><creatorcontrib>Kluger, Benzi M.</creatorcontrib><creatorcontrib>Rodriguez, Ramon L.</creatorcontrib><creatorcontrib>Malaty, Irene A.</creatorcontrib><creatorcontrib>Palacio Jr, Rafael</creatorcontrib><creatorcontrib>Ojo, Oluwadamilola O.</creatorcontrib><creatorcontrib>Patel, Shnehal</creatorcontrib><creatorcontrib>Gujrati, Yogesh</creatorcontrib><creatorcontrib>Nutter, Benjamin</creatorcontrib><creatorcontrib>Swartz, Camille</creatorcontrib><creatorcontrib>Hennessy, Carol</creatorcontrib><creatorcontrib>Fernandez, Hubert H.</creatorcontrib><title>Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease</title><title>Movement disorders</title><addtitle>Mov Disord</addtitle><description>ABSTRACT
Background
Fatigue affects 40% to 50% of all PD patients and is a leading cause of disability, with no clearly established or efficacious established treatments.
Methods
In this double‐blinded, placebo‐controlled, pilot trial, we investigated whether rasagiline improved fatigue among PD patients. Subjects were randomized to 1 mg daily of rasagiline or placebo for 12 weeks. The primary endpoint was a change in the Modified Fatigue Impact Scale from baseline to week 12.
Results
Thirty PD subjects (16 men), with Modified Fatigue Impact Scale baseline score of 67 ± 15, were randomized (16 to rasagiline vs. 14 to placebo). Significant improvement was noted in the mean Modified Fatigue Impact Scale score of the rasagiline group (12 points) as compared to placebo (8.5 points) from baseline to week 12 (P = 0.003).
Conclusion
In this pilot study, rasagiline at a dose of 1 mg per day improved fatigue. Larger randomized studies are needed to confirm this finding. © 2015 International Parkinson and Movement Disorder Society.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Double-Blind Method</subject><subject>fatigue</subject><subject>Fatigue - drug therapy</subject><subject>Fatigue - etiology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Indans - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Movement disorders</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson's disease</subject><subject>Pilot Projects</subject><subject>rasagiline</subject><subject>Severity of Illness Index</subject><subject>Statistics, Nonparametric</subject><subject>Treatment Outcome</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0ctOGzEYBWALgUqALngBZIlFYTHB98uyCiUt4lKlVF1azoxNDXNJ7RlB3r5OE1hUQkJeWLK-_8j2AeAQozFGiJw1VRoTwYjeAiPMKS4U4XIbjJBSvKBY8V2wl9IDQhhzLD6AXSKk0IzrEbic2WTvQx1aB30XYf_bwbRsFn3X2D6UsI_O9o1re9h56PPR_eBgaOF3Gx9Dm7r2U4JVSM4mdwB2vK2T-7jZ98HPiy93k6_F1e302-TzVVEywnQh1dxpzPN9yzn3SnlNrGXCSuGVIJZgXSFJLBJUMcU49xQxKvK9cckqLRjdByfr3EXs_gwu9aYJqXR1bVvXDclgqRDHkur3UIGUpljwTI__ow_dENv8kKx4XlrhlTpdqzJ2KUXnzSKGxsalwcisujC5C_Ovi2yPNonDvHHVq3z5_AzO1uAp1G75dpK5Pv_xElmsJ0Lq3fPrRO7CCEklN79upuZcqpmYikuj6F8Ly58F</recordid><startdate>201511</startdate><enddate>201511</enddate><creator>Lim, Thien Thien</creator><creator>Kluger, Benzi M.</creator><creator>Rodriguez, Ramon L.</creator><creator>Malaty, Irene A.</creator><creator>Palacio Jr, Rafael</creator><creator>Ojo, Oluwadamilola O.</creator><creator>Patel, Shnehal</creator><creator>Gujrati, Yogesh</creator><creator>Nutter, Benjamin</creator><creator>Swartz, Camille</creator><creator>Hennessy, Carol</creator><creator>Fernandez, Hubert H.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201511</creationdate><title>Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease</title><author>Lim, Thien Thien ; Kluger, Benzi M. ; Rodriguez, Ramon L. ; Malaty, Irene A. ; Palacio Jr, Rafael ; Ojo, Oluwadamilola O. ; Patel, Shnehal ; Gujrati, Yogesh ; Nutter, Benjamin ; Swartz, Camille ; Hennessy, Carol ; Fernandez, Hubert H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4249-78be915264cb5f88f92aa46a76f862a219d072a063848455f304365161c4d9643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Double-Blind Method</topic><topic>fatigue</topic><topic>Fatigue - drug therapy</topic><topic>Fatigue - etiology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Indans - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Movement disorders</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson's disease</topic><topic>Pilot Projects</topic><topic>rasagiline</topic><topic>Severity of Illness Index</topic><topic>Statistics, Nonparametric</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lim, Thien Thien</creatorcontrib><creatorcontrib>Kluger, Benzi M.</creatorcontrib><creatorcontrib>Rodriguez, Ramon L.</creatorcontrib><creatorcontrib>Malaty, Irene A.</creatorcontrib><creatorcontrib>Palacio Jr, Rafael</creatorcontrib><creatorcontrib>Ojo, Oluwadamilola O.</creatorcontrib><creatorcontrib>Patel, Shnehal</creatorcontrib><creatorcontrib>Gujrati, Yogesh</creatorcontrib><creatorcontrib>Nutter, Benjamin</creatorcontrib><creatorcontrib>Swartz, Camille</creatorcontrib><creatorcontrib>Hennessy, Carol</creatorcontrib><creatorcontrib>Fernandez, Hubert H.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lim, Thien Thien</au><au>Kluger, Benzi M.</au><au>Rodriguez, Ramon L.</au><au>Malaty, Irene A.</au><au>Palacio Jr, Rafael</au><au>Ojo, Oluwadamilola O.</au><au>Patel, Shnehal</au><au>Gujrati, Yogesh</au><au>Nutter, Benjamin</au><au>Swartz, Camille</au><au>Hennessy, Carol</au><au>Fernandez, Hubert H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov Disord</addtitle><date>2015-11</date><risdate>2015</risdate><volume>30</volume><issue>13</issue><spage>1825</spage><epage>1830</epage><pages>1825-1830</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><coden>MOVDEA</coden><abstract>ABSTRACT
Background
Fatigue affects 40% to 50% of all PD patients and is a leading cause of disability, with no clearly established or efficacious established treatments.
Methods
In this double‐blinded, placebo‐controlled, pilot trial, we investigated whether rasagiline improved fatigue among PD patients. Subjects were randomized to 1 mg daily of rasagiline or placebo for 12 weeks. The primary endpoint was a change in the Modified Fatigue Impact Scale from baseline to week 12.
Results
Thirty PD subjects (16 men), with Modified Fatigue Impact Scale baseline score of 67 ± 15, were randomized (16 to rasagiline vs. 14 to placebo). Significant improvement was noted in the mean Modified Fatigue Impact Scale score of the rasagiline group (12 points) as compared to placebo (8.5 points) from baseline to week 12 (P = 0.003).
Conclusion
In this pilot study, rasagiline at a dose of 1 mg per day improved fatigue. Larger randomized studies are needed to confirm this finding. © 2015 International Parkinson and Movement Disorder Society.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>26769459</pmid><doi>10.1002/mds.26429</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3185 |
| ispartof | Movement disorders, 2015-11, Vol.30 (13), p.1825-1830 |
| issn | 0885-3185 1531-8257 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1780517394 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Double-Blind Method fatigue Fatigue - drug therapy Fatigue - etiology Female Follow-Up Studies Humans Indans - therapeutic use Male Middle Aged Movement disorders Neuroprotective Agents - therapeutic use Parkinson Disease - complications Parkinson's disease Pilot Projects rasagiline Severity of Illness Index Statistics, Nonparametric Treatment Outcome |
| title | Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T21%3A55%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rasagiline%20for%20the%20symptomatic%20treatment%20of%20fatigue%20in%20Parkinson's%20disease&rft.jtitle=Movement%20disorders&rft.au=Lim,%20Thien%20Thien&rft.date=2015-11&rft.volume=30&rft.issue=13&rft.spage=1825&rft.epage=1830&rft.pages=1825-1830&rft.issn=0885-3185&rft.eissn=1531-8257&rft.coden=MOVDEA&rft_id=info:doi/10.1002/mds.26429&rft_dat=%3Cproquest_cross%3E1760893165%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1757579815&rft_id=info:pmid/26769459&rfr_iscdi=true |